The Potential for Xanthine Oxidase Inhibition in the Prevention and Treatment of Cardiovascular and Cerebrovascular Disease. (13th October 2009)

• Record Type: Journal Article
• Authors: Higgins, Peter; Dawson, Jesse; Walters, Matthew
• Other Names: Ikonomovic Milos Academic Editor.
• Is Part Of: Cardiovascular psychiatry and neurology. Volume 2009(2009)
• Publication Date: 2009-10-13
• Subjects: Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Psychological aspects -- Periodicals; Psychiatry -- Periodicals; Cardiology -- Periodicals; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; Cardiology; Cardiovascular system -- Diseases; Cardiovascular system -- Diseases -- Psychological aspects; Nervous system -- Diseases; Neurology; Psychiatry; Cardiovascular Diseases -- complications; Nervous System Diseases -- complications; Mental Disorders -- complications; Cardiology; Neurology; Psychiatry; Cardiovascular Diseases -- complications -- Periodicals; Nervous System Diseases -- complications -- Periodicals; Mental Disorders -- complications -- Periodicals; Cardiology -- Periodicals; Neurology -- Periodicals; Psychiatry -- Periodicals; Periodicals; Electronic journals; 616.81
• DOI: 10.1155/2009/282059
• Languages: English
• ISSNs: 2090-0163

Abstract

Abstract : There is a now a wealth of epidemiological, animal, and clinical data to suggest the benefits of uric acid reduction and hxanthine oxidase inhibition in prevention of vascular disease. This review discusses the available epidemiological, preclinical, and clinical data and considers arguments for and against a role for serum uric acid in common cardiovascular disorders. It concludes that large scale trials with clinical endpoints are justified to address this important question and to define whether use of drugs such as allopurinol should be a routine part of preventative strategies.